Toddler taken to hospital after fall into pool in Detroit
The accident was reported to 911 about 12:30 p.m. A Detroit Fire Department spokesperson said that when firefighters arrived, family members were providing CPR on the 20-month-old boy.
"The crew did a great job and got the child's pulse back on the way to the hospital," the report said.
The child was taken by Detroit EMS to St. John Hospital, where he was listed in critical condition late Wednesday.
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
22 minutes ago
- Yahoo
Experts reveal the hidden health side effects of lash serums
Longer, darker lashes are having a moment. For those avoiding the risk or expense of lash extensions, serums can seem like a safer, more affordable option. But not all lash serums are created equal – and some come with hidden side-effects. The key difference lies in the ingredients. Some lash serums use conditioning agents like peptides or plant oils, while others contain powerful pharmaceutical ingredients originally developed for treating eye disease. In 2001, a new medication called bimatoprost was approved to treat glaucoma and ocular hypertension – two conditions involving pressure buildup inside the eye that can damage the optic nerve and cause vision loss. Unlike earlier treatments, bimatoprost worked well for patients who hadn't responded to other drugs, had fewer systemic side effects (effects on the whole body rather than just the eye) and required less frequent dosing than some other glaucoma drops. But doctors soon noticed something unexpected: their patients' eyelashes were growing longer, thicker and darker. Researchers still don't fully understand how bimatoprost stimulates lash growth, but it appears to extend the anagen phase – the active growth phase – of the lash life cycle. In 2008, the same drug (now marketed as Latisse) was approved by the US Food and Drug Administration (FDA), the federal agency responsible for evaluating the safety and effectiveness of drugs and medical devices, to treat eyelash hypotrichosis, a condition where eyelashes are sparse or missing. It was initially prescribed for people who had lost their lashes due to chemotherapy, alopecia areata (an autoimmune disorder causing hair loss), or trichotillomania (a compulsive hair-pulling condition). Extensive research shows that bimatoprost is effective at making lashes longer, thicker and darker, with noticeable results after 16 weeks of daily use. But the results are temporary: once you stop using it, your lashes return to their natural growth cycle. Side-effects Bimatoprost belongs to a class of medications called prostaglandin analogues (PGAs), which have been widely used in eye care since the 1990s. Because of this, its side effects are well documented. When used for lash growth, bimatoprost can cause burning, redness, dryness and eye irritation. These usually go away when the product is stopped. But there are also more serious cosmetic changes to be aware of, including darkening of the skin on the eyelid, fat loss around the eyes, creating a hollow, sunken look, permanent iris darkening (the coloured part of the eye), unwanted hair growth where the serum spreads and, in rare cases, drooping of the upper eyelid, which may require surgery to correct. In the UK, bimatoprost remains a prescription-only medication. However, the boom in over-the-counter lash serums sold online and in shops has made similar products more accessible – and potentially more confusing. A recent investigation by the UK government found that almost one in four lash serums sold in the UK contain PGAs such as isopropyl cloprostenate. This chemical is not as well studied as bimatoprost, but case reports suggest it can cause skin darkening, dryness and hollowing of the eye area, sometimes after just a few weeks of use. In the US, the FDA issued warnings over a decade ago stating that any cosmetic product containing these ingredients and making growth claims should be treated as a drug, not a cosmetic. Consumers may be unaware they're using a pharmaceutical-mimicking ingredient. Sweden banned PGAs in lash serums in 2013. Canada prohibits them in all cosmetic products. Even if a product claims to be 'PGA-free,' check the ingredients list: anything ending in '-prost' is a red flag. 'Natural' or peptide-based alternatives Some lash serums use peptides, which may help strengthen lashes by boosting keratin or supporting follicle health. These are often combined with conditioning agents to reduce breakage. While seen as a gentler alternative to PGAs, most studies on peptides focus on scalp hair, not eyelashes, so evidence for lash growth is limited. Other serums rely on castor oil or plant-based extracts, but their effectiveness is largely anecdotal and not supported by robust science. There is no guaranteed, side-effect-free way to make lashes grow dramatically longer. Prescription lash serums like bimatoprost are proven to work – but they come with potential risks, especially with long-term use. Over-the-counter products may seem safer, but many contain hidden prostaglandin analogues buried deep in the ingredients list with similar side effects. Peptide and oil-based serums are less risky, but there's little strong evidence that they work. Our eyes are delicate and, unlike beauty trends, they're not replaceable. If you're thinking about enhancing your lashes, read the label, do your research and speak to an eye care professional. The price of longer lashes shouldn't be your eye health. Alison Ng is a Lecturer in Optometry and Vision Sciences at Cardiff University Byki Huntjens is an Honorary Senior Research Fellow in Optometry in the School of Health & Medical Sciences, City St George's at the University of London. This article is republished from The Conversation under a Creative Commons license. Read the original article.
Yahoo
22 minutes ago
- Yahoo
Lee Health gains NMTC financing for new medical facility in US
Lee Health, a not-for-profit health system in the US, has secured a $6m New Markets Tax Credit (NMTC) allocation from UB Community Development (UBCD) on permanent financing for a new medical facility. The financing will facilitate the purchase, along with the installation of equipment in the facility in Fort Myers, Florida, aimed at bolstering healthcare services in a low-income community. The to-be-constructed facility will offer an 85,000ft² medical laboratory and data centre, which will enhance Lee Health's processing and testing capabilities. This expansion is expected to support the health system's existing operations and provide essential medical lab services to more than 100,000 people each year. Lee Health chief operating and financial officer Ben Spence said: "This investment allows Lee Health to expand critical infrastructure that supports the delivery of high-quality, efficient care across our region. "We are grateful for the opportunity to better serve our community, while also creating meaningful jobs and strengthening our ability to meet the growing needs of Southwest Florida." The project is set to create 30 new jobs while retaining 142 existing positions across the facilities of Lee Health. With a network that includes four acute care hospitals, two nursing units, a paediatric hospital, and multiple outpatient centres, the health system provides services for over two million patients annually. It is particularly focused on reaching medically underserved individuals, offering access to social services and primary care that might otherwise be sought in emergency rooms. UB Community Development president Alex Jones said: "With healthcare being so vital to a community and the uncertain future facing providers, UBCD is grateful to be able to support Lee Health in their undertaking.' Earlier this year, North Walton Doctors Hospital received $12.5m in NMTC funding through UBCD for its rehabilitation. "Lee Health gains NMTC financing for new medical facility in US" was originally created and published by Hospital Management, a GlobalData owned brand. The information on this site has been included in good faith for general informational purposes only. It is not intended to amount to advice on which you should rely, and we give no representation, warranty or guarantee, whether express or implied as to its accuracy or completeness. You must obtain professional or specialist advice before taking, or refraining from, any action on the basis of the content on our site.
Wall Street Journal
an hour ago
- Wall Street Journal
The Race to Find a Measles Treatment as Infections Surge
As a record number of people in the U.S. are sickened with measles, researchers are resurrecting the search for something long-deemed redundant: treatments for the viral disease. After the measles vaccine was introduced in the 1960s, cases of the disease plummeted. By 2000, federal officials had declared measles eliminated from the U.S. This success led to little interest in the development of treatments. But now, as vaccination rates fall and infections rise, scientists are racing to develop drugs they say could prevent or treat the disease in vulnerable and unvaccinated people.
